# An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread

> **NCT02737475** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 166 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** BMS-986178
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **BIOLOGICAL:** Tetanus vaccine
- **BIOLOGICAL:** DPV-001 vaccine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT02737475
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-17
- **Primary completion:** 2020-11-02
- **Final completion:** 2020-11-02
- **Target enrollment:** 166 (ACTUAL)
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02737475

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02737475, "An Investigational Immuno-Therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Participants With Solid Cancers That Are Advanced or Have Spread". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02737475. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*